Drug intelligence / Profile preview

Axl CAB-CAR-T

Development stage: Preclinical
Lead developer: Formula 1
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Axl CAB-CAR-T is a conditionally active biologic (CAB) CAR-T cell therapy developed through a collaboration between BioAtla and F1 Oncology. It is designed to target the Axl receptor tyrosine kinase and is engineered to be active only within the tumor microenvironment. This conditional activity aims to reduce off-target toxicities, making it a potentially safer treatment for cancers such as metastatic renal cell carcinoma.

Other names: CAB-CAR-T AXL

Targets

AXL (AXL receptor tyrosine kinase)

Beyond the preview

Go deeper on Axl CAB-CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axl CAB-CAR-T.

Explore the full profile